Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10371344rdf:typepubmed:Citationlld:pubmed
pubmed-article:10371344lifeskim:mentionsumls-concept:C0237401lld:lifeskim
pubmed-article:10371344lifeskim:mentionsumls-concept:C0543482lld:lifeskim
pubmed-article:10371344lifeskim:mentionsumls-concept:C0392360lld:lifeskim
pubmed-article:10371344lifeskim:mentionsumls-concept:C0220908lld:lifeskim
pubmed-article:10371344lifeskim:mentionsumls-concept:C0376571lld:lifeskim
pubmed-article:10371344lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:10371344lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:10371344lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:10371344lifeskim:mentionsumls-concept:C2348519lld:lifeskim
pubmed-article:10371344pubmed:issue3lld:pubmed
pubmed-article:10371344pubmed:dateCreated1999-6-23lld:pubmed
pubmed-article:10371344pubmed:abstractTextSince there is a lack of common family profile among BRCA1-gene carriers, and since the risk of being a mutation carrier is not limited to women with a family history of breast or ovarian cancer, multivariate statistical analysis using the logistic-regression model was carried out, to discriminate between sporadic cases and BRCA1-breast cancers (BRCA1-BCs), especially when information about the family history of breast/ovarian cancer and ethnicity are irrelevant or unavailable, in order to offer specific medical treatment to this population. We examined 32 BRCA1-BCs selected at cancer genetic clinics and 200 consecutive controls without family history of breast cancer for age at onset and current morphological parameters. Following the multivariate analysis, 3 parameters only, namely, early age at cancer onset [odds ratio (OR) for each year = 1.16; p < 0.0001], estrogen-receptor negativity (OR = 5.7; p = 0.01) and poor differentiation (OR = 5; p = 0.03) were found significant factors for predicting BRCA1-carrier status. The expected impact in BRCA1 screening of our model was estimated using data on 5700 breast-cancer cases from a hospital-based registry. Only 50 and 15% of tumours with early age at onset below 35 years present one or the other 2 discriminant parameters respectively. Consequently, whereas the probability of finding a BRCA1 mutation is rated low (6.2%) when the sole criterion of early onset up to the age of 35 years is used, based on our model, in the sub-group of women with a tumor that is both estrogen-receptor-negative and poorly differentiated the mutation-detection rate is predicted to be above the 10% chance level recommended by the ASCO guidelines. This sub-group of women, representing about 1% of all breast-cancer cases in Western countries, consequently deserves to be tested.lld:pubmed
pubmed-article:10371344pubmed:languageenglld:pubmed
pubmed-article:10371344pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10371344pubmed:citationSubsetIMlld:pubmed
pubmed-article:10371344pubmed:statusMEDLINElld:pubmed
pubmed-article:10371344pubmed:monthJunlld:pubmed
pubmed-article:10371344pubmed:issn0020-7136lld:pubmed
pubmed-article:10371344pubmed:authorpubmed-author:NoguchiTTlld:pubmed
pubmed-article:10371344pubmed:authorpubmed-author:BirnbaumDDlld:pubmed
pubmed-article:10371344pubmed:authorpubmed-author:SauvanRRlld:pubmed
pubmed-article:10371344pubmed:authorpubmed-author:LidereauRRlld:pubmed
pubmed-article:10371344pubmed:authorpubmed-author:JacquemierJJlld:pubmed
pubmed-article:10371344pubmed:authorpubmed-author:EisingerFFlld:pubmed
pubmed-article:10371344pubmed:authorpubmed-author:PeyratJ PJPlld:pubmed
pubmed-article:10371344pubmed:authorpubmed-author:SobolHHlld:pubmed
pubmed-article:10371344pubmed:authorpubmed-author:VenninPPlld:pubmed
pubmed-article:10371344pubmed:authorpubmed-author:NoguèsCClld:pubmed
pubmed-article:10371344pubmed:authorpubmed-author:Guinebretière...lld:pubmed
pubmed-article:10371344pubmed:authorpubmed-author:BardouV JVJlld:pubmed
pubmed-article:10371344pubmed:issnTypePrintlld:pubmed
pubmed-article:10371344pubmed:day21lld:pubmed
pubmed-article:10371344pubmed:volume84lld:pubmed
pubmed-article:10371344pubmed:ownerNLMlld:pubmed
pubmed-article:10371344pubmed:authorsCompleteYlld:pubmed
pubmed-article:10371344pubmed:pagination263-7lld:pubmed
pubmed-article:10371344pubmed:dateRevised2007-7-24lld:pubmed
pubmed-article:10371344pubmed:meshHeadingpubmed-meshheading:10371344...lld:pubmed
pubmed-article:10371344pubmed:meshHeadingpubmed-meshheading:10371344...lld:pubmed
pubmed-article:10371344pubmed:meshHeadingpubmed-meshheading:10371344...lld:pubmed
pubmed-article:10371344pubmed:meshHeadingpubmed-meshheading:10371344...lld:pubmed
pubmed-article:10371344pubmed:meshHeadingpubmed-meshheading:10371344...lld:pubmed
pubmed-article:10371344pubmed:meshHeadingpubmed-meshheading:10371344...lld:pubmed
pubmed-article:10371344pubmed:meshHeadingpubmed-meshheading:10371344...lld:pubmed
pubmed-article:10371344pubmed:meshHeadingpubmed-meshheading:10371344...lld:pubmed
pubmed-article:10371344pubmed:meshHeadingpubmed-meshheading:10371344...lld:pubmed
pubmed-article:10371344pubmed:year1999lld:pubmed
pubmed-article:10371344pubmed:articleTitleNovel indications for BRCA1 screening using individual clinical and morphological features.lld:pubmed
pubmed-article:10371344pubmed:affiliationDepartment of Genetic Oncology/INSERM CRI 9703, Paoli-Calmettes Institute, Marseille, France.lld:pubmed
pubmed-article:10371344pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10371344pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10371344lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10371344lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10371344lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10371344lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10371344lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10371344lld:pubmed